You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCyclobenzaprine
Accession NumberDB00924  (APRD00213)
TypeSmall Molecule
GroupsApproved
DescriptionCyclobenzaprine is a skeletal muscle relaxant and a central nervous system (CNS) depressant. Cyclobenzaprine acts on the locus coeruleus where it results in increased norepinephrine release, potentially through the gamma fibers which innervate and inhibit the alpha motor neurons in the ventral horn of the spinal cord. It is structurally similar to Amitriptyline, differing by only one double bond.
Structure
Thumb
Synonyms
(3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-amine
Ciclobenzaprina
Cyclobenzaprine
Cyclobenzaprinum
N,N-Dimethyl-5H-dibenzo(a,D)cycloheptene-delta(5,gamma)-propylamine
N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-cyclobenzaprine - Tab 10mgTablet10 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
AmrixCapsule, extended release15 mg/1OralA S Medication Solutions2007-10-01Not applicableUs
AmrixCapsule, extended release15 mg/1OralSTAT Rx USA LLC2007-10-01Not applicableUs
AmrixCapsule, extended release15 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-01-03Not applicableUs
AmrixCapsule, extended release30 mg/1OralSTAT Rx USA LLC2007-10-01Not applicableUs
AmrixCapsule, extended release15 mg/1OralCephalon, Inc.2007-10-01Not applicableUs
AmrixCapsule, extended release30 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-10-01Not applicableUs
AmrixCapsule, extended release15 mg/1OralRebel Distributors Corp.2007-10-01Not applicableUs
AmrixCapsule, extended release30 mg/1OralCephalon, Inc.2007-10-01Not applicableUs
AmrixCapsule, extended release15 mg/1OralPhysicians Total Care, Inc.2009-04-16Not applicableUs
AmrixCapsule, extended release30 mg/1OralRebel Distributors Corp2007-10-01Not applicableUs
AmrixCapsule, extended release15 mg/1OralA S Medication Solutions2007-10-02Not applicableUs
Auro-cyclobenzaprineTablet10 mgOralAuro Pharma Inc2011-06-15Not applicableCanada
Ava-cyclobenzaprineTablet10 mgOralAvanstra Inc2011-10-112014-08-21Canada
CyclobenzaprineTablet10 mgOralSivem Pharmaceuticals Ulc2014-10-01Not applicableCanada
CyclobenzaprineTablet10 mgOralSanis Health Inc2010-02-25Not applicableCanada
CyclobenzaprineTablet10 mgOralSorres Pharma Inc2009-06-222014-06-20Canada
Cyclobenzaprine-10 - Tab 10mgTablet10 mgOralPro Doc Limitee1997-01-15Not applicableCanada
Dom-cyclobenzaprineTablet10 mgOralDominion Pharmacal1998-10-22Not applicableCanada
Flexeril -(10mg)Tablet10 mgOralJanssen Inc1978-12-312005-08-04Canada
Jamp-cyclobenzaprineTablet10 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-cyclobenzaprineTablet10 mgOralJamp Pharma Corporation2011-10-18Not applicableCanada
Mylan-cyclobenzaprineTablet10 mgOralMylan Pharmaceuticals Ulc1997-05-21Not applicableCanada
Novo-cycloprineTablet10 mgOralTeva Canada Limited1994-12-31Not applicableCanada
Nu-cyclobenzaprine-tab 10mgTablet10 mgOralNu Pharm Inc1995-12-312012-09-04Canada
PHL-cyclobenzaprineTablet10 mgOralPharmel Inc2004-04-06Not applicableCanada
PMS-cyclobenzaprine - Tab 10mgTablet10 mgOralPharmascience Inc1996-12-31Not applicableCanada
Q-cyclobenzaprineTablet10 mgOralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Ratio-cyclobenzaprineTablet10 mgOralRatiopharm Inc Division Of Teva Canada Limited1997-12-162015-10-26Canada
Riva-cyclobenzaprineTablet10 mgOralLaboratoire Riva Inc2000-05-23Not applicableCanada
Zym-cyclobenzaprineTablet10 mgOralZymcan Pharmaceuticals Inc2012-05-282014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cyclobenzaprine - Tab 10mgTablet10 mgOralApotex Inc1995-12-31Not applicableCanada
Comfort Pac With CyclobenzaprineKitPd Rx Pharmaceuticals, Inc.2013-07-15Not applicableUs
CyclobenzaprineTablet, film coated7.5 mg/1OralCitron Pharma LLC2016-10-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralProficient Rx LP2012-03-14Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralAurobindo Pharma Limited2008-09-26Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralA S Medication Solutions2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralPd Rx Pharmaceuticals, Inc.2014-07-31Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralProficient Rx LP2012-04-02Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralNorthwind Pharmaceuticals, LLC2014-11-24Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-04-02Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralQualitest Pharmaceuticals2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideCapsule, film coated, extended release5 mg/1OralSterling Knight Pharmaceuticals,Llc2016-10-31Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralREMEDYREPACK INC.2013-03-13Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated7.5 mg/1OralAidarex Pharmaceuticals LLC2015-03-25Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1Oralbryant ranch prepack2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralAphena Pharma Solutions Tennessee, Llc1989-05-03Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralMc Kesson Contract Packaging2011-09-29Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralMylan Institutional Inc.1997-08-25Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralLake Erie Medical DBA Quality Care Product LLC2010-07-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralA S Medication Solutions2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralKAISER FOUNDATION HOSPITALS2010-03-02Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralPreferred Pharmaceuticals Inc.2016-09-30Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralApotheca Inc.2012-04-02Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralLiberty Pharmaceuticals, Inc.1989-05-03Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralREMEDYREPACK INC.2013-03-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralProficient Rx LP2006-02-03Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralBlenheim Pharmacal, Inc.2010-01-25Not applicableUs
Cyclobenzaprine HydrochlorideTablet7.5 mg/1OralAidarex Pharmaceuticals LLC2011-08-29Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralPd Rx Pharmaceuticals, Inc.2010-05-24Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralRanbaxy Pharmaceuticals Inc2008-05-12Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralContract Pharmacy Services Pa2010-04-23Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated7.5 mg/1OralPreferred Pharmaceuticals, Inc.2015-05-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated7.5 mg/1OralActavis Pharma, Inc.2006-02-03Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralMedsource Pharmaceuticals2012-04-02Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralCitron Pharma LLC2008-09-26Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralSTAT Rx USA LLC2010-04-29Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralClinical Solutions Wholesale2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralUnit Dose Services2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralA S Medication Solutions2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralMylan Pharmaceuticals Inc.2006-02-03Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralRebel Distributors2006-04-19Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralDIRECT RX2014-01-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralReady Meds2010-02-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet7.5 mg/1OralDispensing Solutions, Inc.2011-08-29Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralPhysicians Total Care, Inc.1997-03-17Not applicableUs
Cyclobenzaprine HydrochlorideTablet7.5 mg/1OralProficient Rx LP2011-08-29Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralAurobindo Pharma Limited2008-09-26Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralLegacy Pharmaceutical Packaging2012-04-02Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2014-07-31Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralPreferred Pharmaceuticals, Inc.2011-07-07Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralNorthwind Pharmaceuticals, LLC2015-03-17Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralSt. Mary's Medical Park Pharmacy2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2016-11-04Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralCamber Pharmaceuticals2012-04-02Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralMutual Pharmaceutical1995-05-23Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralJUBILANT CADISTA PHARMACEUTICALS, INC.2006-04-06Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralAmerican Health Packaging2009-10-14Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2006-04-04Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2014-04-30Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-02Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralA S Medication Solutions2014-07-31Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralKAISER FOUNDATION HOSPITALS2015-11-10Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralCipla USA Inc.2016-07-22Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralSTAT Rx USA LLC2010-02-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated7.5 mg/1OralSa3, Llc2015-03-25Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralActavis Pharma, Inc.1989-05-03Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated7.5 mg/1OralMedsource Pharmaceuticals2011-08-29Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralA S Medication Solutions2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralREMEDYREPACK INC.2013-06-09Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralNu Care Pharmaceuticals, Inc.2012-04-02Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralRx Change Co.2014-11-06Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated7.5 mg/1OralRanbaxy Pharmaceuticals Inc2008-05-12Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralRed Pharm Drug Inc.2007-01-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-02-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralKeltman Pharmaceuticals Inc.2006-08-24Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralCitron Pharma LLC2008-09-26Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2010-02-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2014-10-29Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralUnit Dose Services2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralA S Medication Solutions2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralLiberty Pharmaceuticals, Inc.1989-05-03Not applicableUs
Cyclobenzaprine HydrochlorideTablet7.5 mg/1OralDIRECT RX2014-01-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralRebel Distributors2010-02-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated7.5 mg/1OralDIRECT RX2015-01-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralCamber Pharmaceuticals2012-04-02Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralPhysicians Total Care, Inc.2006-05-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralProficient Rx LP2010-02-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralMed Vantx, Inc.1995-09-29Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralLegacy Pharmaceutical Packaging2012-04-02Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralPreferred Pharmaceuticals Inc.2016-04-13Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralPharmaceutica North America, Inc.2013-08-072016-10-13Us
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralPreferred Pharmaceuticals, Inc.2014-02-26Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralBreckenridge Pharmaceutical, Inc.2006-12-06Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralREMEDYREPACK INC.2016-05-16Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated7.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-03-25Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralSTAT Rx USA LLC2010-04-29Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralMutual Pharmaceutical1995-05-23Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralJUBILANT CADISTA PHARMACEUTICALS, INC.2006-04-04Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2007-06-14Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralAmerican Health Packaging2014-05-30Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated7.5 mg/1OralKLE 2, Inc.2011-08-292015-12-29Us
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralPliva Inc.1995-09-292016-10-31Us
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralA S Medication Solutions2014-07-31Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralMylan Pharmaceuticals Inc.1991-05-30Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralCipla USA Inc.2016-07-22Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralRed Pharm Drug Inc.2010-07-12Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralSolubiomix2015-08-262016-04-05Us
Cyclobenzaprine HydrochlorideTablet10 mg/1OralMajor Pharmaceuticals1988-02-29Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralREMEDYREPACK INC.2011-04-262016-10-13Us
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralA S Medication Solutions2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralREMEDYREPACK INC.2013-05-22Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralLegacy Pharmaceutical Packaging, Llc2016-07-22Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralKvk Tech, Inc.2014-07-31Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-02Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2010-02-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralRanbaxy Pharmaceuticals Inc2008-05-12Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralDIRECT RX2014-01-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-02-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralKeltman Pharmaceuticals Inc.2010-06-10Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated7.5 mg/1OralAll Pharma, Llc2015-03-25Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralPd Rx Pharmaceuticals, Inc.2006-12-06Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralProficient Rx LP1989-05-03Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/301OralNorthwind Pharmaceuticals2014-05-16Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralA S Medication Solutions2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralQualitest Pharmaceuticals2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralRed Pharm Drug, Inc.1989-05-03Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralBlenheim Pharmacal, Inc.2012-03-30Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralDIRECT RX2016-11-16Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralAidarex Pharmaceuticals LLC2010-02-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralCardinal Health2011-07-15Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated7.5 mg/1OralProficient Rx LP2015-03-25Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralDispensing Solutions, Inc.1989-05-03Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralPreferred Pharmaceuticals, Inc.2015-04-22Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralActavis Pharma, Inc.2006-02-03Not applicableUs
Cyclobenzaprine HydrochlorideTablet7.5 mg/1OralPreferred Pharmaceuticals, Inc.2012-05-082016-12-31Us
Cyclobenzaprine HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2013-02-252016-10-13Us
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralREMEDYREPACK INC.2016-05-27Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralREMEDYREPACK INC.2016-08-16Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated7.5 mg/1OralMylan Pharmaceuticals Inc.2013-04-24Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralTmig Inc1989-05-03Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralGolden State Medical Supply, Inc.2006-02-03Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralDispensing Solutions, Inc.2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralSTAT Rx USA LLC2010-04-29Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralClinical Solutions Wholesale2010-02-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1Oralbryant ranch prepack2010-02-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralRed Pharm Drug Inc.2010-02-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/10mgOralAlivio Medical Products, Llc2015-10-01Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralAv Pak2014-06-10Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2012-03-052016-10-22Us
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralA S Medication Solutions2007-02-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralREMEDYREPACK INC.2014-02-06Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralLegacy Pharmaceutical Packaging, Llc2016-07-22Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralKvk Tech, Inc.2014-07-31Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-04-23Not applicableUs
Cyclobenzaprine Hydrochloride KitKitPharmaceutica North America, Inc.2013-08-282016-10-13Us
Cyclobenzaprine HyrochlorideTablet7.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-08-29Not applicableUs
Cyclobenzaprine HyrochlorideTablet7.5 mg/1Oralbryant ranch prepack2011-08-29Not applicableUs
Cyclobenzaprine HyrochlorideTablet7.5 mg/1OralH.J. Harkins Company, Inc.2011-08-29Not applicableUs
Cyclobenzaprine HyrochlorideTablet7.5 mg/1OralRebel Distributors Corp2011-08-29Not applicableUs
Cyclobenzaprine HyrochlorideTablet7.5 mg/1OralUnit Dose Services2011-08-29Not applicableUs
FexmidTablet, film coated7.5 mg/1OralVictory Pharma, Inc.2008-11-012016-10-13Us
FexmidTablet, film coated7.5 mg/1OralShionogi Inc.2011-10-01Not applicableUs
FexmidTablet, film coated7.5 mg/1OralRebel Distributors Corp2008-11-01Not applicableUs
FexmidTablet, film coated7.5 mg/1OralSTAT Rx USA LLC2008-11-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cyclobenzaprine HydrochlorideCapsule, film coated, extended release10 mg/1OralSterling Knight Pharmaceuticals,Llc2016-10-31Not applicableUs
TabradolKitOralFusion Pharmaceuticals LLC2009-09-17Not applicableUs
TabradolKitOralCalifornia Pharmaceuticals, Llc2016-01-01Not applicableUs
International Brands
NameCompany
FlexerilJanssen
FlexibanSIT
Brand mixtures
NameLabellerIngredients
Cyclo/magLiving Well Pharmacy, Inc.
Cyclo/mag 10mg/200mgLiving Well Pharmacy, Inc.
Gapeam BudibacAlvix Laboratories, LLC
Therabenzaprine-60Physician Therapeutics Llc
Therabenzaprine-90Physician Therapeutics Llc
Therabenzaprine-90-5Physician Therapeutics Llc
Salts
Name/CASStructureProperties
Cyclobenzaprine Hydrochloride
6202-23-9
Thumb
  • InChI Key: VXEAYBOGHINOKW-UHFFFAOYSA-N
  • Monoisotopic Mass: 311.144077416
  • Average Mass: 311.848
DBSALT000479
Categories
UNII69O5WQQ5TI
CAS number303-53-7
WeightAverage: 275.3874
Monoisotopic: 275.167399677
Chemical FormulaC20H21N
InChI KeyJURKNVYFZMSNLP-UHFFFAOYSA-N
InChI
InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3
IUPAC Name
dimethyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}propyl)amine
SMILES
CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12
Pharmacology
IndicationFor use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.
Structured Indications
PharmacodynamicsCyclobenzaprine, closely related to the antidepressant amitriptyline, is used as a skeletal muscle relaxant to reduce pain and tenderness and improve mobility. Unlike dantrolene, cyclobenzaprine cannot be used to treat muscle spasm secondary to cerebral or spinal cord disease.
Mechanism of actionLike other tricyclic antidepressants, cyclobenzaprine exhibits anticholinergic activity, potentiation of norepinephrine, and antagonism of reserpine. Cyclobenzaprine does not directly act on the neuromuscular junction or the muscle but relieves muscle spasms through a central action, possibly at the brain stem level. Cyclobenzaprine binds to the serotonin receptor and is considered a 5-HT2 receptor antagonist that reduces muscle tone by decreasing the activity of descending serotonergic neurons.
TargetKindPharmacological actionActionsOrganismUniProt ID
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
Related Articles
AbsorptionSlowly but well absorbed after oral administration
Volume of distributionNot Available
Protein bindingVery high (93%)
Metabolism

Extensively metabolized (gastrointestinal and hepatic).

SubstrateEnzymesProduct
Cyclobenzaprine
desmethylcyclobenzaprineDetails
Route of eliminationCyclobenzaprine is extensively metabolized, and is excreted primarily as glucuronides via the kidney.
Half life18 hours (range 8-37 hours)
Clearance
  • 0.7 L/min
ToxicityOral mouse and rat LD50 are 338 mg/kg and 425 mg/kg respectively. Signs of overdose include agitation, coma, confusion, congestive heart failure, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high or low temperature, increased heartbeats, irregular heart rhythms, muscle stiffness, overactive reflexes, severe low blood pressure, stupor, and vomiting.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
1,10-PhenanthrolineThe serum concentration of Cyclobenzaprine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineCyclobenzaprine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Cyclobenzaprine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineCyclobenzaprine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineCyclobenzaprine may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Cyclobenzaprine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
4-Bromo-2,5-dimethoxyamphetamineCyclobenzaprine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineCyclobenzaprine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINECyclobenzaprine may increase the serotonergic activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe serum concentration of Cyclobenzaprine can be increased when it is combined with Abiraterone.Approved
AcenocoumarolCyclobenzaprine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Acetophenazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with adipiplon.Investigational
AgmatineCyclobenzaprine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cyclobenzaprine.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Cyclobenzaprine.Approved, Investigational
AlogliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Cyclobenzaprine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyclobenzaprine.Approved, Illicit, Investigational
AltretamineAltretamine may increase the orthostatic hypotensive activities of Cyclobenzaprine.Approved
AmiodaroneThe metabolism of Cyclobenzaprine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyclobenzaprine.Approved
AmobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyclobenzaprine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amperozide.Experimental
AmphetamineCyclobenzaprine may increase the stimulatory activities of Amphetamine.Approved, Illicit
AmprenavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Amprenavir.Approved
Antithrombin III humanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Apixaban.Approved
ApomorphineCyclobenzaprine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineCyclobenzaprine may decrease the antihypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Cyclobenzaprine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Cyclobenzaprine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aripiprazole.Approved, Investigational
ArtemetherThe metabolism of Cyclobenzaprine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Asenapine.Approved
AsunaprevirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Cyclobenzaprine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Cyclobenzaprine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Azaperone.Vet Approved
AzelastineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Azelastine.Approved
AzithromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Baclofen.Approved
BambuterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bambuterol.Approved
BarbexacloneThe metabolism of Cyclobenzaprine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinCyclobenzaprine may increase the serotonergic activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benzocaine.Approved
BenzphetamineCyclobenzaprine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Cyclobenzaprine can be decreased when combined with Betaxolol.Approved
BethanidineCyclobenzaprine may decrease the antihypertensive activities of Bethanidine.Approved
BexaroteneThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Cyclobenzaprine can be increased when it is combined with Bi201335.Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bifeprunox.Investigational
BivalirudinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Cyclobenzaprine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Cyclobenzaprine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brexpiprazole.Approved
BrimonidineCyclobenzaprine may decrease the antihypertensive activities of Brimonidine.Approved
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Cyclobenzaprine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromazepam.Approved, Illicit
BromocriptineCyclobenzaprine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyclobenzaprine.Approved, Investigational
BuprenorphineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Cyclobenzaprine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyclobenzaprine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclobenzaprine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclobenzaprine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Cyclobenzaprine.Approved
CaffeineThe metabolism of Cyclobenzaprine can be decreased when combined with Caffeine.Approved
CandoxatrilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Cyclobenzaprine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carfentanil.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carisoprodol.Approved
CaroxazoneCyclobenzaprine may increase the serotonergic activities of Caroxazone.Withdrawn
CelecoxibThe metabolism of Cyclobenzaprine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cyclobenzaprine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Cyclobenzaprine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorphenamine.Approved
ChlorphentermineCyclobenzaprine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Cyclobenzaprine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Cyclobenzaprine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
ChymostatinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Cyclobenzaprine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cyclobenzaprine.Approved, Vet Approved
CirazolineCyclobenzaprine may increase the vasopressor activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Cyclobenzaprine can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clenbuterol.Approved, Vet Approved
ClidiniumThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clidinium.Approved
ClobazamThe metabolism of Cyclobenzaprine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clonazepam.Approved, Illicit
ClonidineCyclobenzaprine may decrease the antihypertensive activities of Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclobenzaprine.Approved, Illicit
ClotrimazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Cyclobenzaprine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Cyclobenzaprine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclobenzaprine.Approved, Illicit
ConivaptanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Cyclobenzaprine can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyclizine.Approved
CyclosporineThe metabolism of Cyclobenzaprine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Cyclobenzaprine can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cyclobenzaprine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Cyclobenzaprine.Investigational
DarifenacinThe metabolism of Cyclobenzaprine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Cyclobenzaprine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dexbrompheniramine.Approved
DexmedetomidineCyclobenzaprine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Cyclobenzaprine.Approved
DextroamphetamineCyclobenzaprine may increase the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Cyclobenzaprine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyclobenzaprine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Cyclobenzaprine.Approved, Illicit, Vet Approved
DicoumarolCyclobenzaprine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionCyclobenzaprine may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineCyclobenzaprine may decrease the antihypertensive activities of Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Cyclobenzaprine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Cyclobenzaprine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Diphenoxylate.Approved, Illicit
DipivefrinCyclobenzaprine may decrease the antihypertensive activities of Dipivefrin.Approved
DobutamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Cyclobenzaprine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doxepin.Approved
DoxycyclineThe metabolism of Cyclobenzaprine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Illicit
DronedaroneThe metabolism of Cyclobenzaprine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Drotebanol.Experimental, Illicit
DroxidopaCyclobenzaprine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Cyclobenzaprine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclobenzaprine.Approved
EcabetThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Elafin.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Cyclobenzaprine.Approved, Investigational
EliglustatThe metabolism of Cyclobenzaprine can be decreased when combined with Eliglustat.Approved
EnalaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Cyclobenzaprine can be increased when it is combined with Enalkiren.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Cyclobenzaprine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Enzalutamide.Approved
EphedraCyclobenzaprine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineCyclobenzaprine may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergonovine.Approved
ErgotamineCyclobenzaprine may decrease the antihypertensive activities of Ergotamine.Approved
ErythromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyclobenzaprine.Approved
EthanolCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyclobenzaprine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethotoin.Approved
Ethyl biscoumacetateCyclobenzaprine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etizolam.Approved
EtomidateCyclobenzaprine may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclobenzaprine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flibanserin.Approved
FluconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fludiazepam.Approved, Illicit
FluindioneCyclobenzaprine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Cyclobenzaprine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyclobenzaprine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyclobenzaprine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclobenzaprine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cyclobenzaprine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Cyclobenzaprine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Frovatriptan.Approved, Investigational
FurazolidoneCyclobenzaprine may increase the serotonergic activities of Furazolidone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with gabapentin enacarbil.Approved
GabexateThe serum concentration of Cyclobenzaprine can be increased when it is combined with Gabexate.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GeldanamycinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Geldanamycin.Experimental
GepironeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Glutethimide.Approved, Illicit
GM6001The serum concentration of Cyclobenzaprine can be increased when it is combined with GM6001.Experimental
GranisetronGranisetron may increase the serotonergic activities of Cyclobenzaprine.Approved, Investigational
GuanabenzCyclobenzaprine may decrease the antihypertensive activities of Guanabenz.Approved
GuanfacineCyclobenzaprine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Cyclobenzaprine.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Cyclobenzaprine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Heroin.Approved, Illicit
HexobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Hexobarbital.Approved
HirulogThe serum concentration of Cyclobenzaprine can be increased when it is combined with Hirulog.Experimental
HydracarbazineCyclobenzaprine may increase the serotonergic activities of Hydracarbazine.Approved
HydrocodoneCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclobenzaprine.Approved, Illicit
Hydroxyamphetamine hydrobromideCyclobenzaprine may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
IdelalisibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Cyclobenzaprine can be increased when it is combined with idraparinux.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Iloperidone.Approved
ImatinibThe metabolism of Cyclobenzaprine can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cyclobenzaprine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Cyclobenzaprine can be decreased when combined with Indinavir.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Cyclobenzaprine.Approved
IproclozideCyclobenzaprine may increase the serotonergic activities of Iproclozide.Withdrawn
IproniazidCyclobenzaprine may increase the serotonergic activities of Iproniazid.Withdrawn
IsavuconazoniumThe metabolism of Cyclobenzaprine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidCyclobenzaprine may increase the serotonergic activities of Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Cyclobenzaprine.Approved, Vet Approved
IsoflurophateThe serum concentration of Cyclobenzaprine can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Cyclobenzaprine can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Isoprenaline.Approved
IsradipineThe metabolism of Cyclobenzaprine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ixazomib.Approved
KetamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lamotrigine.Approved, Investigational
LepirudinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Lepirudin.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclobenzaprine.Approved
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Cyclobenzaprine.Approved
LidocaineThe metabolism of Cyclobenzaprine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Cyclobenzaprine.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Cyclobenzaprine.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Cyclobenzaprine.Approved
LisdexamfetamineCyclobenzaprine may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Cyclobenzaprine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lofentanil.Illicit
LofexidineCyclobenzaprine may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Cyclobenzaprine can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cyclobenzaprine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lorcaserin.Approved
LovastatinThe metabolism of Cyclobenzaprine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cyclobenzaprine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Cyclobenzaprine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Cyclobenzaprine can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Cyclobenzaprine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Maprotiline.Approved
MebanazineCyclobenzaprine may increase the serotonergic activities of Mebanazine.Withdrawn
MeclizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Melperone.Approved
MephedroneCyclobenzaprine may increase the stimulatory activities of Mephedrone.Investigational
MephentermineCyclobenzaprine may increase the vasopressor activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclobenzaprine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mesoridazine.Approved
MetaraminolCyclobenzaprine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cyclobenzaprine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineCyclobenzaprine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe metabolism of Cyclobenzaprine can be increased when combined with Methohexital.Approved
MethotrimeprazineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineCyclobenzaprine may increase the vasopressor activities of Methoxamine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methsuximide.Approved
Methylene blueCyclobenzaprine may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Cyclobenzaprine.Approved, Investigational
MethylphenobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Cyclobenzaprine.Approved, Investigational
MetoprololThe metabolism of Cyclobenzaprine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineCyclobenzaprine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Cyclobenzaprine can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyclobenzaprine.Approved, Illicit
MidodrineCyclobenzaprine may increase the vasopressor activities of Midodrine.Approved
MifepristoneThe serum concentration of Cyclobenzaprine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Milnacipran.Approved
MinaprineCyclobenzaprine may increase the serotonergic activities of Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Investigational
MirabegronThe metabolism of Cyclobenzaprine can be decreased when combined with Mirabegron.Approved
MirtazapineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Mitotane.Approved
MMDACyclobenzaprine may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideCyclobenzaprine may increase the serotonergic activities of Moclobemide.Approved
ModafinilThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclobenzaprine.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Cyclobenzaprine.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Cyclobenzaprine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Investigational
NafamostatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclobenzaprine.Approved
NaphazolineCyclobenzaprine may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Naratriptan.Approved, Investigational
NCX 4016The serum concentration of Cyclobenzaprine can be increased when it is combined with NCX 4016.Investigational
NefazodoneThe metabolism of Cyclobenzaprine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Cyclobenzaprine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Cyclobenzaprine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Cyclobenzaprine can be increased when combined with Nevirapine.Approved
NialamideCyclobenzaprine may increase the serotonergic activities of Nialamide.Withdrawn
NicardipineThe metabolism of Cyclobenzaprine can be decreased when combined with Nicardipine.Approved
NicorandilCyclobenzaprine may increase the hypotensive activities of Nicorandil.Approved
NilotinibThe metabolism of Cyclobenzaprine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nitrazepam.Approved
NitroaspirinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nitrous oxide.Approved, Vet Approved
NorepinephrineCyclobenzaprine may decrease the antihypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Cyclobenzaprine.Approved
OctamoxinCyclobenzaprine may increase the serotonergic activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclobenzaprine.Approved, Investigational
OlaparibThe metabolism of Cyclobenzaprine can be decreased when combined with Olaparib.Approved
OlodaterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Omapatrilat.Investigational
OndansetronOndansetron may increase the serotonergic activities of Cyclobenzaprine.Approved
OpiumThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Orciprenaline.Approved
OrphenadrineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyclobenzaprine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Cyclobenzaprine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclobenzaprine.Approved, Illicit, Investigational
OxymetazolineCyclobenzaprine may decrease the antihypertensive activities of Oxymetazoline.Approved
OxymorphoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Palbociclib.Approved
PaliperidoneCyclobenzaprine may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Cyclobenzaprine.Approved, Investigational
PanobinostatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineCyclobenzaprine may increase the serotonergic activities of Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Cyclobenzaprine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclobenzaprine.Approved, Vet Approved
PentobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
PerazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perazine.Investigational
PergolideCyclobenzaprine may decrease the antihypertensive activities of Pergolide.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cyclobenzaprine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclobenzaprine.Approved
PhenelzineCyclobenzaprine may increase the serotonergic activities of Phenelzine.Approved
PhenindioneCyclobenzaprine may increase the anticoagulant activities of Phenindione.Approved
PheniprazineCyclobenzaprine may increase the serotonergic activities of Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenoxyethanol.Approved
PhenoxypropazineCyclobenzaprine may increase the serotonergic activities of Phenoxypropazine.Withdrawn
PhenprocoumonCyclobenzaprine may increase the anticoagulant activities of Phenprocoumon.Approved
PhentermineCyclobenzaprine may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineCyclobenzaprine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineCyclobenzaprine may decrease the antihypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Cyclobenzaprine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Cyclobenzaprine can be increased when it is combined with Phosphoramidon.Experimental
PimozideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipotiazine.Approved
PirbuterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Piritramide.Investigational
PirlindoleCyclobenzaprine may increase the serotonergic activities of Pirlindole.Approved
PivhydrazineCyclobenzaprine may increase the serotonergic activities of Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleCyclobenzaprine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cyclobenzaprine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Cyclobenzaprine.Approved
PrimidoneThe metabolism of Cyclobenzaprine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Prinomastat.Investigational
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Cyclobenzaprine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Procaterol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclobenzaprine.Approved, Vet Approved
PromazineThe metabolism of Cyclobenzaprine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Cyclobenzaprine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Cyclobenzaprine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclobenzaprine.Approved
PSD502The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with PSD502.Investigational
PseudoephedrineCyclobenzaprine may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quetiapine.Approved
QuinaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineCyclobenzaprine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineThe metabolism of Cyclobenzaprine can be decreased when combined with Quinine.Approved
RacecadotrilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ramipril.Approved
RanolazineThe metabolism of Cyclobenzaprine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineCyclobenzaprine may increase the serotonergic activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclobenzaprine.Approved
RemikirenThe serum concentration of Cyclobenzaprine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cyclobenzaprine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cyclobenzaprine.Approved
RifabutinThe metabolism of Cyclobenzaprine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Cyclobenzaprine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cyclobenzaprine can be increased when combined with Rifapentine.Approved
RisperidoneCyclobenzaprine may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ritanserin.Investigational
RitobegronCyclobenzaprine may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ritodrine.Approved
RitonavirThe metabolism of Cyclobenzaprine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Rizatriptan.Approved
RolapitantThe metabolism of Cyclobenzaprine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Romifidine.Vet Approved
RopiniroleCyclobenzaprine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyclobenzaprine.Approved
RotigotineCyclobenzaprine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Cyclobenzaprine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with S-Ethylisothiourea.Experimental
SafrazineCyclobenzaprine may increase the serotonergic activities of Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sage 547.Investigational
SalbutamolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Salmeterol.Approved
SaquinavirThe metabolism of Cyclobenzaprine can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineCyclobenzaprine may increase the serotonergic activities of Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Cyclobenzaprine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Cyclobenzaprine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Sitagliptin.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
SpiraprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Cyclobenzaprine can be increased when combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Cyclobenzaprine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclobenzaprine.Approved, Investigational
SulfisoxazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyclobenzaprine.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Cyclobenzaprine.Approved, Investigational
SuvorexantCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tasimelteon.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Cyclobenzaprine.Approved
TelaprevirThe metabolism of Cyclobenzaprine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyclobenzaprine.Approved
TemocaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Temocapril.Experimental, Investigational
TenofovirThe metabolism of Cyclobenzaprine can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Cyclobenzaprine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Terbutaline.Approved
TeriflunomideThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrodotoxin.Investigational
ThalidomideCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Cyclobenzaprine can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Cyclobenzaprine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Cyclobenzaprine can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thioproperazine.Approved
ThioridazineThe metabolism of Cyclobenzaprine can be decreased when combined with Thioridazine.Approved
ThiorphanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiothixene.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Cyclobenzaprine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiapride.Investigational
TiclopidineThe metabolism of Cyclobenzaprine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiletamine.Vet Approved
TipranavirThe metabolism of Cyclobenzaprine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineCyclobenzaprine may decrease the antihypertensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneCyclobenzaprine may increase the serotonergic activities of Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Topiramate.Approved
TramadolCyclobenzaprine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineCyclobenzaprine may increase the serotonergic activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineCyclobenzaprine may increase the serotonergic activities of Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyclobenzaprine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyclobenzaprine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclobenzaprine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cyclobenzaprine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cyclobenzaprine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Triprolidine.Approved
TropisetronTropisetron may increase the serotonergic activities of Cyclobenzaprine.Investigational
UbenimexThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ubenimex.Experimental
Uc1010The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Uc1010.Investigational
UlinastatinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe serum concentration of Cyclobenzaprine can be increased when it is combined with Valproic Acid.Approved, Investigational
VemurafenibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Cyclobenzaprine.Approved
VerapamilThe metabolism of Cyclobenzaprine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vigabatrin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vilazodone.Approved
VildagliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Vildagliptin.Approved, Investigational
VoriconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vortioxetine.Approved
WarfarinCyclobenzaprine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Xylazine.Vet Approved
XylometazolineCyclobenzaprine may decrease the antihypertensive activities of Xylometazoline.Approved
Ym150The serum concentration of Cyclobenzaprine can be increased when it is combined with Ym150.Investigational
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Cyclobenzaprine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Cyclobenzaprine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Cyclobenzaprine.Approved, Investigational
ZolpidemCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.
References
Synthesis Reference

Villani, F.J.; US. Patent 3,409,640; November 5,1968; assigned to Schering Corporation.

General ReferencesNot Available
External Links
ATC CodesM03BX08
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelDownload (230 KB)
MSDSDownload (73.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9512
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7567
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.6447
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.7826
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7501
CYP450 1A2 substrateInhibitor0.7324
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9158
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6955
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8127
BiodegradationNot ready biodegradable0.8727
Rat acute toxicity2.9697 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7531
hERG inhibition (predictor II)Inhibitor0.6767
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Anesta ag
  • Actavis totowa llc
  • Aurobindo pharma ltd
  • Cadista pharmaceuticals inc
  • Invagen pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Orit laboratories llc
  • Pliva inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • Mcneil pediatrics
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseOral15 mg/1
Capsule, extended releaseOral30 mg/1
TabletOral10 mg
Kit
Capsule, film coated, extended releaseOral10 mg/1
Capsule, film coated, extended releaseOral5 mg/1
TabletOral10 mg/1
TabletOral10 mg/10mg
TabletOral5 mg/1
TabletOral7.5 mg/1
Tablet, film coatedOral10 mg/301
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral7.5 mg/1
Kit
KitTopical
KitOral
Prices
Unit descriptionCostUnit
Cyclobenzaprine hcl crystal273.88USD g
Cyclobenzaprine hcl powder35.84USD g
Fexmid 7.5 mg tablet4.18USD tablet
Flexeril 5 mg tablet2.04USD tablet
Flexeril 10 mg tablet1.74USD tablet
Cyclobenzaprine HCl 5 mg tablet1.71USD tablet
Cyclobenzaprine 5 mg tablet1.64USD tablet
Cyclobenzaprine HCl 10 mg tablet0.47USD tablet
Cyclobenzaprine 10 mg tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7387793 No2005-02-262025-02-26Us
US7544372 No2003-11-142023-11-14Us
US7790199 No2003-11-142023-11-14Us
US7820203 No2003-11-142023-11-14Us
US7829121 No2003-11-142023-11-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
boiling point173-177Not Available
water solubilityFreely SolubleNot Available
logP5.2Not Available
pKa8.47Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00689 mg/mLALOGPS
logP4.73ALOGPS
logP4.61ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity102.62 m3·mol-1ChemAxon
Polarizability32.95 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene connected by a cycloheptene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassDibenzocycloheptenes
Sub ClassNot Available
Direct ParentDibenzocycloheptenes
Alternative Parents
Substituents
  • Dibenzocycloheptene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Honda M, Nishida T, Ono H: Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol. 2003 Jan 1;458(1-2):91-9. [PubMed:12498911 ]
  2. Kobayashi H, Hasegawa Y, Ono H: Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol. 1996 Sep 5;311(1):29-35. [PubMed:8884233 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91. [PubMed:8818577 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91. [PubMed:8818577 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:39